Back to Search Start Over

Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy: a prospective single-centre clinical trial

Authors :
Hannah M Garcia Garrido
Bridget van Put
Sanne Terryn
Cornelis A de Pijper
Cornelis Stijnis
Geert R D’Haens
Phyllis I Spuls
Marleen G van de Sande
Steven van Gucht
Martin P Grobusch
Abraham Goorhuis
Internal medicine
Infectious diseases
AII - Infectious diseases
General Internal Medicine
APH - Global Health
APH - Quality of Care
Gastroenterology and Hepatology
AGEM - Amsterdam Gastroenterology Endocrinology Metabolism
Dermatology
APH - Methodology
AII - Inflammatory diseases
Clinical Immunology and Rheumatology
APH - Aging & Later Life
Source :
Journal of Travel Medicine, 30(2). Wiley-Blackwell, Journal of travel medicine, 30(2). Wiley-Blackwell, Garcia Garrido, H M, van Put, B, Terryn, S, de Pijper, C A, Stijnis, C, D'Haens, G R, Spuls, P I, van de Sande, M G, van Gucht, S, Grobusch, M P & Goorhuis, A 2023, ' Immunogenicity and 1-year boostability of a three-dose intramuscular rabies pre-exposure prophylaxis schedule in adults receiving immunosuppressive monotherapy : a prospective single-centre clinical trial ', Journal of Travel Medicine, vol. 30, no. 2 . https://doi.org/10.1093/jtm/taac148
Publication Year :
2022
Publisher :
Oxford University Press (OUP), 2022.

Abstract

Background For immunocompromised patients (ICPs), administration of rabies immunoglobulins (RIG) after exposure is still recommended regardless of prior vaccination, due to a lack of data. We aimed to assess the 1-year boostability of a three-dose rabies pre-exposure prophylaxis (PrEP) schedule in individuals using immunosuppressive monotherapy. Methods In this prospective study, individuals on immunosuppressive monotherapy with a conventional immunomodulator (cIM) or a TNF-alpha inhibitor (TNFi) for a chronic inflammatory disease received a three-dose intramuscular PrEP schedule (days 0,7,21–28) with 1 mL Rabipur®, followed by a two-dose simulated post-exposure prophylaxis (PEP) schedule (days 0,3) after 12 months. Rabies neutralizing antibodies were assessed at baseline, on day 21–28 (before the third PrEP dose), day 60, month 12 and month 12 + 7 days. The primary outcome was 1-year boostability, defined as the proportion of patients with a neutralizing antibody titre of ≥ 0.5 IU/mL at month 12 + 7 days. Secondary outcomes were geometric mean titres (GMTs) and factors associated with the primary endpoint. Results We included 56 individuals, of whom 52 completed the study. The 1-year boostability was 90% (47/52) with a GMT of 6.16 (95% CI 3.83–9.91). All participants seroconverted at some point in the study. Early response to PrEP (at day 21–28) was significantly associated with 100% boostability (Odds Ratio 51; 95% confidence interval [5.0–6956], P Conclusion In patients using immunosuppressive monotherapy, a three-dose rabies PrEP schedule followed by a two-dose PEP schedule is immunogenic, with all patients seroconverting at some point in the study. Although boostability 7 days after PEP was not 100%, nobody would wrongly be denied RIG when only administered to those who responded early to PrEP while reducing the administration of RIG by 73%.

Details

ISSN :
17088305 and 11951982
Volume :
30
Database :
OpenAIRE
Journal :
Journal of Travel Medicine
Accession number :
edsair.doi.dedup.....5fdb1d7850de0d7468fe047e98398aa7